Ponořte se důkladně do všech možností Oracle Database 11g a objevte jeho nové funkce a nástroje. Autoři vás mimo jiné naučí dokonale využívat dotazy SQL, příkazy jazyka PL/SQL, pracovat s velkými objekty a objektově-relačními databázemi, implementovat nejnovější bezpečnostní opatření nebo ladit výkon databáze. V referenčních přílohách také naleznete seznamy příkazů, klíčových slov a funkcí.

• MeSH
• Databases as Topic MeSH
• Computer Communication Networks MeSH
• Computer Systems MeSH
• Software MeSH

• Conspectus
• Programové vybavení. Programové prostředky

• MeSH
• Biological Science Disciplines MeSH
• Databases as Topic utilization   MeSH

• Conspectus
• Biologické vědy
• NML Fields
• biologie
• lékařská informatika
• NML Publication type
• elektronické časopisy

Ať jste zkušeným či začínajícím databázovým administrátorem (DBA), potřebujete znát vyspělé nástroje Oracle Database 11g a vědět, jak vám mohou usnadnit vaši práci. V publikaci od nejzkušenějších světových expertů poznáte plánování, správu a údržbu všech aspektů databáze, nástroje a techniky pro maximalizaci výkonu, dostupnosti a zabezpečení, implementaci aplikací, řešení nejrůznějších problémů, Oracle Net atd.

• MeSH
• Databases as Topic MeSH
• Computer Communication Networks MeSH
• Computer Systems MeSH

• Conspectus
• Programování. Software

The most widely used specialized chemistry databases and web services allowing access to them will be described. Besides the largest commercial three (Reaxys, SciFinder, Web of Science), some freely available services (Google Scholar, ChemSpider , PubChem, PubMed) will also be discussed. Strong and weak points of the presented databases will be emphasised and recommendations for optimal database selection and searching will be given.

• Keywords
• Reaxys, SciFinder, Web of Science, Google Scholar, ChemSpider, PubChem,
• MeSH
• Databases, Chemical * economics   classification   MeSH
• Databases as Topic classification   MeSH
• Information Storage and Retrieval MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH
• Review MeSH

Biological membranes act as barriers or reservoirs for many compounds within the human body. As such, they play an important role in pharmacokinetics and pharmacodynamics of drugs and other molecular species. Until now, most membrane/drug interactions have been inferred from simple partitioning between octanol and water phases. However, the observed variability in membrane composition and among compounds themselves stretches beyond such simplification as there are multiple drug-membrane interactions. Numerous experimental and theoretical approaches are used to determine the molecule-membrane interactions with variable accuracy, but there is no open resource for their critical comparison. For this reason, we have built Molecules on Membranes Database (MolMeDB), which gathers data about over 3600 compound-membrane interactions including partitioning, penetration and positioning. The data have been collected from scientific articles published in peer-reviewed journals and complemented by in-house calculations from high-throughput COSMOmic approach to set up a baseline for further comparison. The data in MolMeDB are fully searchable and browsable by means of name, SMILES, membrane, method or dataset and we offer the collected data openly for further reuse and we are open to further additions. MolMeDB can be a powerful tool that could help researchers better understand the role of membranes and to compare individual approaches used for the study of molecule/membrane interactions.

• MeSH
• Databases, Chemical * MeSH
• Humans MeSH
• Membranes MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

• MeSH
• Databases, Factual MeSH
• Software MeSH

Recent studies indicate that ambient temperature may modulate obstructive sleep apnoea (OSA) severity. However, study results are contradictory warranting more investigation in this field. We analysed 19,293 patients of the European Sleep Apnoea Database (ESADA) cohort with restriction to the three predominant climate zones according to the Köppen-Geiger climate classification: Cfb (warm temperature, fully humid, warm summer), Csa (warm temperature, summer dry, hot summer), and Dfb (snow, fully humid, warm summer). Average outside temperature values were obtained and several hierarchical regression analyses were performed to investigate the impact of temperature on the apnea-hypopnea index (AHI), oxygen desaturation index (ODI), time of oxygen saturation <90% (T90) and minimum oxygen saturation (MinSpO2 ) after controlling for confounders including age, body mass index, gender, and air conditioning (A/C) use. AHI and ODI increased with higher temperatures with a standardised coefficient beta (β) of 0.28 for AHI and 0.25 for ODI, while MinSpO2 decreased with a β of -0.13 (all results p < .001). When adjusting for climate zones, the temperature effect was only significant in Cfb (AHI: β = 0.11) and Dfb (AHI: β = 0.08) (Model 1: p < .001). The presence of A/C (3.9% and 69.3% in Cfab and Csa, respectively) demonstrated only a minor increase in the prediction of the variation (Cfb: AHI, R2 +0.003; and Csa: AHI, R2 +0.007; both p < .001). Our present study indicates a limited but consistent influence of environmental temperature on OSA severity and this effect is modulated by climate zones.

• MeSH
• Body Mass Index MeSH
• Cohort Studies MeSH
• Humans MeSH
• Sleep Apnea, Obstructive * diagnosis   epidemiology   MeSH
• Sleep Apnea Syndromes * MeSH
• Temperature MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

AIMS: We analysed longitudinal blood pressure (BP) data from hypertensive obstructive sleep apnoea (OSA) patients in the European Sleep Apnea Database cohort. The study investigated the interaction between positive airway pressure (PAP)-induced BP change and antihypertensive treatment (AHT). METHODS AND RESULTS: Hypertensive patients with AHT [monotherapy/dual therapy n = 1283/652, mean age 59.6 ± 10.7/60.6 ± 10.3 years, body mass index (BMI) 34.2 ± 6.5/34.8 ± 7.0 kg/m2, apnoea-hypopnoea index 46 ± 25/46 ± 24 n/h, proportion female 29/26%, respectively] started PAP treatment. Office BP at baseline and 2- to 36-month follow-up were assessed. The interaction between AHT drug classes and PAP on BP was quantified and the influences of age, gender, BMI, co-morbidities, BP at baseline, and study site were evaluated. Following PAP treatment (daily usage, 5.6 ± 1.6/5.7 ± 1.9 h/day), systolic BP was reduced by -3.9 ± 15.5/-2.8 ± 17.7 mmHg in mono/dual AHT and diastolic BP by -3.0 ± 9.8/-2.7 ± 10.8 mmHg, respectively, all P < 0.0001. Systolic and diastolic BP control was improved following PAP treatment (38/35% to 54/46% and 67/67% to 79/74%, mono/dual AHT, respectively). PAP treatment duration predicted a larger BP improvement in the monotherapy group. Intake of renin-angiotensin blockers [angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)] alone or in any AHT combination was associated with better BP control. The AHT-dependent BP improvement was independent of confounders. CONCLUSION: In this pan-European OSA patient cohort, BP control improved following initiation of PAP. Longer PAP treatment duration, was associated with a favourable effect on BP. Our study suggests that ACEI/ARB, alone or in combination with other drug classes, provides a particularly strong reduction of BP and better BP control when combined with PAP in OSA.

• Publication type
• Journal Article MeSH

STUDY OBJECTIVES: To assess the impact of the non-respiratory arousal burden at baseline polysomnography (PSG) on residual daytime sleepiness in positive airway pressure (PAP)-treated obstructive sleep apnea (OSA). METHODS: We included OSA patients from the European Sleep Apnea Database registry with available arousal data who had at least 2 treatment follow-up visits. The primary outcome was the Epworth Sleepiness Scale (ESS) score under PAP. The non-respiratory arousal ratio (NRAR) was defined as the ratio of non-respiratory to total arousals at baseline PSG. A linear mixed model tested the effect of NRAR tertiles on residual sleepiness. Baseline variables that differed significantly between groups were included as covariates. RESULTS: 800 patients with OSA (69.6 % male, mean age 57.1 ± 12.0 years, mean NRAR 0.22 ± 0.20) were evaluated during three follow up visits at a mean of 197.4, 499.3, and 731.6 days after PAP initiation. The interaction between time and NRAR tertile was statistically significant (F = 4.55, p = 0.001). The lowest NRAR tertile was associated with lower residual sleepiness over time compared to the highest NRAR tertile. The associations were independent of sex, comorbidities, body mass index, blood pressure, baseline apnea-hypopnea index, and baseline ESS score. CONCLUSIONS: NRAR at baseline PSG predicts residual sleepiness in PAP-treated OSA patients. The findings offer new insights into OSA phenotyping and have important implications for patient care.

• MeSH
• Arousal * physiology   MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Sleep Apnea, Obstructive * therapy   physiopathology   complications   MeSH
• Polysomnography * MeSH
• Disorders of Excessive Somnolence physiopathology   MeSH
• Registries * MeSH
• Aged MeSH
• Sleepiness MeSH
• Continuous Positive Airway Pressure * MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Geographicals
• Europe MeSH